Compare TKLF & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | CALC |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2M | 9.7M |
| IPO Year | 2020 | 2020 |
| Metric | TKLF | CALC |
|---|---|---|
| Price | $1.98 | $0.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 106.3K | ★ 297.3K |
| Earning Date | 12-19-2025 | 05-13-2026 |
| Dividend Yield | ★ 10.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $2.82 | $3.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $0.46 |
| 52 Week High | $4.32 | $7.20 |
| Indicator | TKLF | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 61.03 |
| Support Level | N/A | $0.52 |
| Resistance Level | $2.41 | $0.93 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 14.92 | 59.67 |
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.